+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Forecast 2024-2030- Product Image
Global Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Forecast 2024-2030- Product Image
Sale

Global Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967607
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bivalirudin Market size was estimated at USD 1.23 billion in 2023, USD 1.31 billion in 2024, and is expected to grow at a CAGR of 6.13% to reach USD 1.87 billion by 2030.

Bivalirudin is a medication primarily used as an anticoagulant, which helps prevent blood clot formation. Bivalirudin belongs to a class of drugs known as direct thrombin inhibitors, which reduces the likelihood of clots forming in the blood vessels. This is especially important in situations where blood clots can lead to severe health issues such as heart attacks, strokes, or blockages in the arteries or veins. An increase in the global incidence of heart diseases has led to a higher need for effective treatment options, including angioplasty, where bivalirudin plays a critical role.

Moreover, the significant potential for innovation in formulating bivalirudin to enhance its efficacy and reduce side effects led to more effective and safer anticoagulant options. However, the high cost of bivalirudin and related medical procedures limit its accessibility to a broader patient base. In addition, the presence of alternative anticoagulants and new drugs entering the market may challenge bivalirudin adoption among end-users. Nevertheless, an increase in healthcare infrastructure investments and spending, along with a rising burden of cardiovascular diseases, is improving the adoption of advanced drug medications. The ongoing exploration of bivalirudin in combination with other drugs is expected to open new therapeutic areas and extend the application of bivalirudin in the coming years.

Regional Insights

The high prevalence of heart diseases and the advanced healthcare infrastructure stimulate the need for bivalirudin in the Americas. Customer purchasing behavior leans towards trust in clinically proven medications, with bivalirudin being preferred for its efficiency in reducing bleeding complications. European countries showcase a uniform approach towards Bivalirudin, which has been greatly influenced by European Union (EU) regulations and healthcare guidelines. The adoption varies with national healthcare systems, availability, and reimbursement policies.

The growing aging population and an increase in cardiovascular diseases underscore a steady need for bivalirudin in the European Union (EU). In the Middle East and Africa, the market for Bivalirudin is emerging due to increasing investments in healthcare and collaborations with international health organizations. The Asia Pacific region represents a dynamic market for bivalirudin due to the government's push towards healthcare reform and investment in hospital infrastructure.

Market Trends by Segment

  • Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
  • End-Use: Emerging usage of bivalirudin in ambulatory surgical centers

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.

Avenacy, a provider of essential injectables, officially launched its Bivalirudin Injection in the United States, matching the therapeutic equivalence of Angiomax for Injection (bivalirudin). This approval, granted by the U.S. Food and Drug Administration, allows the medication to be used as an anticoagulant during percutaneous coronary interventions (PCI), benefitting patients, including those who suffer from heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome.

Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency

Endo International announced the introduction of a Bivalirudin Injection, available in a user-friendly 250mg/50mL single-use vial format. This development is particularly significant for patients undergoing percutaneous coronary intervention, including those with heparin-induced complications. The innovative ready-to-use solution is designed to streamline the medication administration process, significantly reducing the likelihood of preparation errors.

Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection

Endo International plc, through its subsidiary Endo Ventures Limited, announced a pivotal agreement with MAIA Pharmaceuticals, Inc. for the U.S. distribution of a bivalirudin injection in a ready-to-use (RTU) format. This partnership underscores both companies' commitment to enhancing healthcare delivery by providing an RTU solution that eliminates the preparation process, thereby increasing efficiency in hospital settings, reducing the potential for error, and supporting the highest standards of patient care.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy’s Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

This research report offers invaluable insights into various crucial aspects of the Bivalirudin Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
5.1.1.2. Growing consumer expenditure for improved drug and medications
5.1.2. Restraints
5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
5.1.3. Opportunities
5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
5.1.3.2. Ongoing government approvals for new products
5.1.4. Challenges
5.1.4.1. Risks and complexities associated with use of bivalirudin
5.2. Market Segmentation Analysis
5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Bivalirudin Market, by Dosage Form
6.1. Introduction
6.2. Injection
6.3. Powder
7. Bivalirudin Market, by Application
7.1. Introduction
7.2. Angioplasty
7.3. Heparin-induced Thrombocytopenia
7.4. Percutaneous Coronary Intervention
8. Bivalirudin Market, by End-Use
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals & Clinics
8.4. Specialty Clinics
9. Americas Bivalirudin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bivalirudin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bivalirudin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIVALIRUDIN MARKET DYNAMICS
FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 49. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 50. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 51. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 52. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 53. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 54. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 55. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 56. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 57. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 58. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 59. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 60. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 83. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 84. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 85. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 86. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 87. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 88. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 89. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 90. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 91. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 92. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 93. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 94. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 101. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 102. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 103. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 104. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 105. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 106. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 137. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 138. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 139. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 142. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 157. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 158. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 159. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 160. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 161. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 162. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 163. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 164. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 165. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 166. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 167. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 168. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 169. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 170. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 171. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 174. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 175. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 176. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 177. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 178. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 179. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 180. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 181. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 182. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 183. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 184. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 185. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 193. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 194. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 195. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 196. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 197. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 198. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 211. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 212. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 213. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 216. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 217. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 218. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 219. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 220. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 221. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 222. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 223. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 224. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 225. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 226. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 227. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 228. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 247. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 248. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 249. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 252. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 265. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 266. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 267. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 268. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 269. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 270. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 283. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Apotex Inc.
  • Aurobindo Pharma
  • Avenacy, Inc.
  • Baxter International
  • Cayman Chemical
  • Cipla Limited
  • Dr. Reddy’s Laboratories
  • Endo International plc
  • Eugia US LLC
  • Fresenius Kabi
  • Meitheal Pharmaceuticals, Inc.
  • Merck KGaA
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.87 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From
Bivalirudin (CAS 128270-60-0) Global Market Research Report 2024 - Product Image

Bivalirudin (CAS 128270-60-0) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Heparin-Induced Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Heparin-Induced Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 118 Pages
  • Global
From
Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F - Product Image

Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • Report
  • 178 Pages
  • Global
From
Global Heparin Market by Product Type (Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin, Unfractionated Heparin), Route of Administration (IV Injection, Subcutaneous Injection), Application, End-User - Forecast 2024-2030 - Product Image

Global Heparin Market by Product Type (Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin, Unfractionated Heparin), Route of Administration (IV Injection, Subcutaneous Injection), Application, End-User - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From

About the Market

Bivalirudin is a cardiovascular drug used to treat and prevent blood clots in patients undergoing coronary angioplasty and other procedures. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the formation of blood clots. Bivalirudin is administered intravenously and is often used in combination with other anticoagulants. It is also used to treat patients with unstable angina and non-ST-segment elevation myocardial infarction. Bivalirudin is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2000. It has become increasingly popular in recent years due to its efficacy and safety profile. It is also cost-effective compared to other anticoagulants, making it an attractive option for healthcare providers. Several companies are involved in the bivalirudin market, including AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Merck, and Sanofi. These companies manufacture and market bivalirudin-based products, such as Angiomax and Refludan. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.